187 related articles for article (PubMed ID: 28193735)
1. Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.
Weinberg BA; Gowen K; Lee TK; Ou SI; Bristow R; Krill L; Almira-Suarez MI; Ali SM; Miller VA; Liu SV; Klempner SJ
Oncologist; 2017 Feb; 22(2):152-157. PubMed ID: 28193735
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
[TBL] [Abstract][Full Text] [Related]
3. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
4. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive genomic profiling of malignant phyllodes tumors of the breast.
Nozad S; Sheehan CE; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon S; Schrock AB; Hirshfield KM; Ali N; Ganesan S; Ali SM; Miller VA; Stephens PJ; Ross JS; Chung JH
Breast Cancer Res Treat; 2017 Apr; 162(3):597-602. PubMed ID: 28210881
[TBL] [Abstract][Full Text] [Related]
6. Comparative genomic analysis of primary tumors and metastases in breast cancer.
Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M
Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851
[TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.
Vignot S; Frampton GM; Soria JC; Yelensky R; Commo F; Brambilla C; Palmer G; Moro-Sibilot D; Ross JS; Cronin MT; André F; Stephens PJ; Lazar V; Miller VA; Brambilla E
J Clin Oncol; 2013 Jun; 31(17):2167-72. PubMed ID: 23630207
[TBL] [Abstract][Full Text] [Related]
8. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.
Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M
JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099
[TBL] [Abstract][Full Text] [Related]
9. Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing.
Alkner S; Tang MH; Brueffer C; Dahlgren M; Chen Y; Olsson E; Winter C; Baker S; Ehinger A; Rydén L; Saal LH; Fernö M; Gruvberger-Saal SK
Breast Cancer Res; 2015 Aug; 17(1):102. PubMed ID: 26242876
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy.
Prendergast EN; Holman LL; Liu AY; Lai TS; Campos MP; Fahey JN; Wang X; Abdelaal N; Rao JY; Elvin JA; Moore KM; Konecny GE; Cohen JG
Gynecol Oncol; 2019 Sep; 154(3):461-466. PubMed ID: 31257009
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.
Fehniger JE; Berger AA; Juckett L; Elvin J; Levine DA; Zajchowski DA
Gynecol Oncol; 2019 Dec; 155(3):473-482. PubMed ID: 31703812
[TBL] [Abstract][Full Text] [Related]
12. Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour.
Huang KT; Mikeska T; Li J; Takano EA; Millar EK; Graham PH; Boyle SE; Campbell IG; Speed TP; Dobrovic A; Fox SB
BMC Cancer; 2015 Oct; 15():669. PubMed ID: 26452468
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice.
Ida H; Koyama T; Mizuno T; Sunami K; Kubo T; Sudo K; Tao K; Hirata M; Yonemori K; Kato K; Okusaka T; Ohe Y; Matsui Y; Yamazaki N; Ogawa C; Kawai A; Narita Y; Esaki M; Yamamoto N
Cancer Sci; 2022 Dec; 113(12):4300-4310. PubMed ID: 36106376
[TBL] [Abstract][Full Text] [Related]
14. Using Genomics to Differentiate Multiple Primaries From Metastatic Lung Cancer.
Murphy SJ; Harris FR; Kosari F; Barreto Siqueira Parrilha Terra S; Nasir A; Johnson SH; Serla V; Smadbeck JB; Halling GC; Karagouga G; Sukov WR; Leventakos K; Yang P; Peikert T; Mansfield AS; Wigle DA; Yi ES; Kipp BR; Vasmatzis G; Aubry MC
J Thorac Oncol; 2019 Sep; 14(9):1567-1582. PubMed ID: 31103780
[TBL] [Abstract][Full Text] [Related]
15. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Genomic Profiling of Central Giant Cell Lesions Identifies Clinically Relevant Genomic Alterations.
Bezak B; Lehrke H; Elvin J; Gay L; Schembri-Wismayer D; Viozzi C
J Oral Maxillofac Surg; 2017 May; 75(5):955-961. PubMed ID: 27883876
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.
Ali SM; Pal SK; Wang K; Palma NA; Sanford E; Bailey M; He J; Elvin JA; Chmielecki J; Squillace R; Dow E; Morosini D; Buell J; Yelensky R; Lipson D; Frampton GM; Howley P; Ross JS; Stephens PJ; Miller VA
Oncologist; 2016 Jan; 21(1):33-9. PubMed ID: 26670666
[TBL] [Abstract][Full Text] [Related]
18. Genomic landscape of pancreatic neuroendocrine tumors.
Gebauer N; Schmidt-Werthern C; Bernard V; Feller AC; Keck T; Begum N; Rades D; Lehnert H; Brabant G; Thorns C
World J Gastroenterol; 2014 Dec; 20(46):17498-506. PubMed ID: 25516664
[TBL] [Abstract][Full Text] [Related]
19. Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country.
Cifuentes C; Lombana M; Vargas H; Laguado P; Ruiz-Patiño A; Rojas L; Navarro U; Vargas C; Ricaurte L; Arrieta O; Zatarain-Barron L; Zapata L; González G; Ortiz C; Bernal L; Restrepo JG; Viola L; Grosso F; Zapata R; Mantilla W; Carranza H; Bustillo I; Llinas N; Duarte R; Rodríguez J; Archila P; Ávila J; Bermúdez M; Gámez T; Sotelo C; Otero J; Forero E; Lema M; Limpias C; Ordóñez-Reyes C; Mejía S; Rolfo C; Rosell R; Cardona AF; ;
Cancer Control; 2023; 30():10732748231175256. PubMed ID: 37148308
[TBL] [Abstract][Full Text] [Related]
20. The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review.
Klempner SJ; Ou SH; Costa DB; VanderLaan PA; Sanford EM; Schrock A; Gay L; Ali SM; Miller VA
Clin Lung Cancer; 2015 Sep; 16(5):334-339.e1. PubMed ID: 25911330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
